Palatin Technologies(PTN) - 2024 Q1 - Earnings Call Presentation

CORPORATE PRESENTATION February 2024 Stephen T. Wills, CPA/MST CFO / COO 2 3 Vyleesi®(bremelanotide) Hypoactive Sexual Desire Disorder * These programs are planned but dependent on funding. Ophthalmology MCr Programs Conjunctiva/Cornea/Ocular surface • Glaucoma | --- | --- | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|------- ...